Please ensure Javascript is enabled for purposes of website accessibility

Why Collegium Pharmaceutical Rose Nearly 10% on Tuesday

By Eric Volkman - Feb 9, 2021 at 6:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's not every day that a company graduates to a slot in a high-profile stock index.

What happened

At times, the reason or reasons behind a stock's rise are obscure or mysterious. But that certainly wasn't the case with Collegium Pharmaceutical (COLL 4.54%) on Tuesday, which shot 9.8% higher thanks to a development that should dramatically raise its profile.

So what

Collegium, a biotech that has enjoyed success with its pain relief medication Xtampza ER, is about to become a component of the S&P stock index family.

Late Monday, S&P Dow Jones Indices -- the operator of the famous suite of indexes -- announced a change in its benchmark S&P 500 index.

A woman looking at a giant screen filled with indexes and graphs

Image source: Getty Images.

S&P 500 index component TechnipFMC is getting the boot and being replaced by Monolithic Power Systems. The latter is currently in the S&P MidCap 400 index, so its slot there will be filled by Iridium Communications.

Iridium is now on the S&P SmallCap 600 index, thus a replacement is needed for its position; Collegium is that replacement. The move is slated to take effect this Friday, Feb. 12.

Now what

Inclusion on a notable stock index, particularly one with the characters "S&P" in front of it and particularly for a less-known business like Collegium, instantly raises its visibility. It also, crucially, attracts the many index funds that prowl S&P lineups for their portfolios.

Naturally, greater prominence and attention doesn't necessarily mean an endless stock price lift -- Collegium still has to deliver for shareholders. But this is an extremely positive development for a company that has performed well lately.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Collegium Pharmaceutical, Inc. Stock Quote
Collegium Pharmaceutical, Inc.
COLL
$15.64 (4.54%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.